Stock comparison
Halozyme Therapeutics
Integer
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
ITGR
Integer
Market cap
$3.03B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | ITGR | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 48D | HALO |
| Benjamin Graham | 83A | 65B | HALO |
| Philip Fisher | 65B | 34F | HALO |
| Peter Lynch | 53D | 57C | ITGR |
| Joel Greenblatt | 40D | 38D | HALO |
| Charlie Munger | 80C | 42D | HALO |
| Terry Smith | 84A | 41D | HALO |
Side-by-side metrics
| Metric | HALO | ITGR |
|---|---|---|
| Market cap | $8.1B | $3.03B |
| P/E (TTM) | 24.0x | 21.3x |
| EV/EBIT | 10.2x | 20.9x |
| ROIC (TTM) | 23.65% | 5.35% |
| Gross margin | 81.24% | 23.31% |
| Net margin | 23.13% | 7.67% |
| Revenue CAGR 5y | 33.23% | 10.89% |
| EPS CAGR 5y | -1.98% | 1.22% |
| Debt / Equity | 1.0x | 0.8x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- ROIC (TTM)23.65%vs 5.35%+77%
- Gross margin81.24%vs 23.31%+71%
- Revenue CAGR 5y33.23%vs 10.89%+67%
- Net margin23.13%vs 7.67%+67%
ITGR leads on
- EPS CAGR 5y1.22%vs -1.98%+162%
- Debt / Equity0.8xvs 1.0x+14%
- P/E (TTM)21.3xvs 24.0x+11%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.